Dianthus Therapeutics Reports Material Agreement, Unregistered Equity Sales

TL;DR

**Dianthus just raised capital via private share sales, good for cash, bad for dilution.**

AI Summary

Dianthus Therapeutics, Inc. filed an 8-K on January 22, 2024, to report an entry into a material definitive agreement and unregistered sales of equity securities. This indicates the company has secured new funding or entered a significant partnership, likely through private placement of shares, which could dilute existing shareholders but also provides capital for operations. For investors, this matters because while it injects capital, the dilution from unregistered sales could impact per-share value.

Why It Matters

This filing signals Dianthus Therapeutics has raised capital, which is crucial for a pharmaceutical company's R&D, but the method of unregistered equity sales could dilute current shareholders.

Risk Assessment

Risk Level: medium — The risk is medium because while new capital is positive, the method of unregistered equity sales often leads to dilution for existing shareholders.

Analyst Insight

A smart investor would monitor for details on the material definitive agreement and the terms of the unregistered equity sales to assess the extent of dilution and the strategic value of the new capital.

Key Players & Entities

• Dianthus Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 22, 2024 (date) — date of earliest event reported and filing date
• 001-38541 (other) — Commission File Number for Dianthus Therapeutics

Forward-Looking Statements

• Dianthus Therapeutics will likely use the newly raised capital to fund ongoing research and development for its pharmaceutical preparations. (Dianthus Therapeutics, Inc.) — high confidence, target: 2024-12-31
• The stock price of Dianthus Therapeutics may experience short-term volatility due to the market's reaction to potential dilution from the unregistered equity sales. (Dianthus Therapeutics, Inc.) — medium confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
• $12 — Common Stock"), at a price per share of $12.00, and (ii) pre-funded warrants (the "
• $11.999 — Warrant Shares") at a purchase price of $11.999 per Pre-Funded Warrant, which represent
• $230 million — gregate purchase price of approximately $230 million. The Pre-Funded Warrants will be exer

Filing Documents

• d699582d8k.htm (8-K) — 33KB
• d699582dex41.htm (EX-4.1) — 69KB
• d699582dex101.htm (EX-10.1) — 299KB
• d699582dex102.htm (EX-10.2) — 156KB
• d699582dex991.htm (EX-99.1) — 11KB
• g699582g0119134757173.jpg (GRAPHIC) — 4KB
• 0001193125-24-011681.txt ( ) — 818KB
• dnth-20240122.xsd (EX-101.SCH) — 3KB
• dnth-20240122_lab.xml (EX-101.LAB) — 18KB
• dnth-20240122_pre.xml (EX-101.PRE) — 11KB
• d699582d8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On January 22, 2024, Dianthus Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") for a private placement (the "Private Placement") with certain institutional and accredited investors (each, a "Purchaser" and collectively, the "Purchasers"). The closing of the Private Placement is expected to occur on January 24, 2024. Pursuant to the Purchase Agreement, the Purchasers have agreed to purchase (i) an aggregate of 14,500,500 shares (the "Common Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a price per share of $12.00, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase an aggregate of 4,666,332 shares of Common Stock (the "Pre-Funded Warrant Shares") at a purchase price of $11.999 per Pre-Funded Warrant, which represents the per share purchase price of the Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate purchase price of approximately $230 million. The Pre-Funded Warrants will be exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. The Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Purchasers, on the other hand, and customary conditions to closing. Also on January 22, 2024, the Company entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Purchasers, which provides that the Company will register the res

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in Item 1.01 above are incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 22, 2024, the Company made available a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including the information in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, including the information in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1 Securities Purchase Agreement, dated January 22, 2024, by and between Dianthus Therapeutics, Inc. and each purchaser identified on Annex A thereto. 10.2 Form of Registration Rights Agreement. 99.1 Press Release, dated January 22, 2024. 104 The cover page from the Company's Current Report on Form 8-K formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: January 22, 2024 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR